ERBB2 and cancer: The present study successfully established in vitro methodology that aimed to measure gold-labelled specific monoclonal antibodies targeted to specific cancer cells; trastuzumab and rituximab to HER2-positive SKBR3 breast cancer and Raji B-cell lymphoma, respectively.